SEC Form 4 · accession 0000899243-16-015091
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark W Frohlich
Officer — See Remarks
Period of report
Feb 29, 2016
Accepted (ET)
Mar 2, 2016 · 9:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3,F4 | Feb 29, 2016 | S | 19,700 | $35.2483 | D | 919,883 | D | |
| Common StockF2,F3,F4 | Feb 29, 2016 | S | 300 | $36.50 | D | 919,583 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $34.79 to $35.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices ranging from $36.40 to 36.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014 and amended on March 20, 2015.
- F4Includes 2,083 shares acquired under the issuer's employee stock purchase plan on November 16, 2015.
Remarks
Executive Vice President, Portfolio Strategy